# Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

> **NCT00866918** · PHASE3 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 106 (actual)

## Conditions studied

- Childhood Acute Promyelocytic Leukemia With PML-RARA
- Myeloid Neoplasm

## Interventions

- **DRUG:** Arsenic Trioxide
- **DRUG:** Cytarabine
- **OTHER:** Diagnostic Laboratory Biomarker Analysis
- **DRUG:** Idarubicin
- **DRUG:** Mercaptopurine
- **DRUG:** Methotrexate
- **DRUG:** Mitoxantrone Hydrochloride
- **DRUG:** Tretinoin

## Key facts

- **NCT ID:** NCT00866918
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03-09
- **Primary completion:** 2015-06-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2022-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00866918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00866918, "Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00866918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*